Targeting Hepatic Glucokinase in Type 2 Diabetes Weighing the Benefits and Risks

被引：54

|

作者：

Agius, Loranne ^{[1
]}

机构：

[1] Univ Newcastle, Sch Med, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England

来源：

DIABETES | 2009年 / 58卷 / 01期

关键词：

REGULATORY PROTEIN; GLUCOSE-HOMEOSTASIS; GLYCOGEN-METABOLISM; TRIGLYCERIDE LEVELS; FASTING GLUCOSE; FATTY RATS; LIVER; ACTIVATORS; DEFECT; LOCI;

D O I：

10.2337/db08-1470

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：18 / 20

页数：3

相关论文

共 50 条

[31] Weighing seafood's benefits, risks
不详
CHEMICAL & ENGINEERING NEWS, 2006, 84 (43) : 46 - 46
[32] Cholesterol reduction: Weighing the benefits and risks
Gaziano, JM
Hebert, PR
Hennekens, CH
ANNALS OF INTERNAL MEDICINE, 1996, 124 (10) : 914 - 918
[33] Semaglutide: weighing up the benefits and risks
Moody, Joe
LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (08): : 520 - 520
[34] Weighing the risks and benefits of tamoxifen - Response
Gail, M
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2003, 168 (01) : 13 - 13
[35] Weighing Benefits and Risks Glucocorticoids and Thromboembolism
Katz, Mitchell H.
JAMA INTERNAL MEDICINE, 2013, 173 (09) : 752 - 752
[36] Weighing the benefits and risks of inhaled corticosteroids
Varkey, Basil
CURRENT OPINION IN PULMONARY MEDICINE, 2007, 13 (02) : 89 - 89
[37] Multiple benefits of targeting inflammation in the treatment of type 2 diabetes
Donath, Marc Y.
DIABETOLOGIA, 2016, 59 (04) : 679 - 682
[38] Multiple benefits of targeting inflammation in the treatment of type 2 diabetes
Marc Y. Donath
Diabetologia, 2016, 59 : 679 - 682
[39] Cardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus
Weidman-Evans, Emily
Metz, Steven M.
Evans, Jeffery D.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (02) : 225 - 233
[40] Targeting hepatic glucose metabolism in the treatment of type 2 diabetes
Rines, Amy K.
Sharabi, Kfir
Tavares, Clint D. J.
Puigserver, Pere
NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (11) : 786 - 804

← 1 2 3 4 5 →